| Literature DB >> 31961685 |
Yi-Hui Peng1, Fang-Yu Liao1, Chen-Tso Tseng1, Ramajayam Kuppusamy1, An-Siou Li1, Chi-Han Chen1, Yu-Shiou Fan1, Sing-Yi Wang1, Mine-Hsine Wu1, Ching-Cheng Hsueh1, Jia-Yu Chang1, Lung-Chun Lee1, Chuan Shih1, Kak-Shan Shia1, Teng-Kuang Yeh1, Ming-Shiu Hung1, Ching-Chuan Kuo1, Jen-Shin Song1, Su-Ying Wu1, Shau-Hua Ueng1,2.
Abstract
Indoleamine 2,3-dioxygenase (IDO1) inhibitors are speculated to be useful in cancer immunotherapy, but a phase III clinical trial of the most advanced IDO1 inhibitor, epacadostat, did not meet its primary end point and was abandoned. In previous work, we identified the novel IDO1 inhibitor N-(4-chlorophenyl)-2-((5-phenylthiazolo[2,3-c][1,2,4]triazol-3-yl)thio)acetamide 1 through high-throughput screening (HTS). Herein, we report a structure-activity relationship (SAR) study of this compound, which resulted in the potent IDO1 inhibitor 1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea 47 (hIDO IC50 = 16.4 nM). X-ray cocrystal structural analysis revealed that the basis for this high potency is a unique sulfur-aromatic interaction network formed by the thiourea moiety of 47 with F163 and F226. This finding is expected to inspire new approaches toward the discovery of potent IDO1 inhibitors in the future.Entities:
Year: 2020 PMID: 31961685 DOI: 10.1021/acs.jmedchem.9b01549
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446